Objective To analyze the clinical effect and safety of epalrestat combined with pentoxifylline in the treat-ment of diabetic foot.Methods A total of 68 patients with diabetic foot admitted to Lanzhou Traditional Chinese Medi-cine Hospital from March 2021 to March 2024 were selected as the research objects.They were divided into two groups according to different medication methods,with 34 cases in each group.The control group was treated with ep-alrestat,and the observation group was treated with epalrestat combined with pentoxifylline.The therapeutic effect,dorsal artery blood supply index,inflammatory factor level,incidence of adverse reactions and quality of life were com-pared between the two groups.Results The total effective rate of the observation group was higher than that of the con-trol group,and the difference was statistically significant(P<0.05).The inner diameter,pulsatility index and blood flow velocity of dorsalis pedis artery in the observation group were higher than those in the control group,the resis-tance index was lower than that in the control group,and the differences were statistically significant(all P<0.05).The levels of C-reactive protein,interleukin-6 and tumor necrosis factor-α in the observation group were lower than those in the control group,and the differences were statistically significant(all P<0.05).The incidence of adverse re-actions in the observation group was lower than that in the control group,and the difference was statistically signifi-cant(P<0.05).The scores of social function,physical quality,role function and emotional function in the observation group were higher than those in the control group,and the differences were statistically significant(all P<0.05).Conclusion Patients with diabetic foot were treated with epalrestat combined with pentoxifylline has a good therapeu-tic effect,high safety,and can improve the quality of life of patients,the clinical application value is significant.
NETL
NSTL
万方数据
